Rafferty Asset Management
CRDF icon

Rafferty Asset Management’s Cardiff Oncology CRDF Stock Holding History

Rafferty Asset Management’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-37,805
Closed -$680K – 1163
2020
Q4 		$680K Buy
+37,805
New +$664K 0.01% 613

Other funds holding CRDF

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $1.85M AUM 176.16% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Rafferty Asset Management's CRDF Position: Q1 2021 in Review

Rafferty Asset Management sold out of Cardiff Oncology (CRDF) in Q1 2021, closing a stake of 37,805 shares — an estimated $680K sold.

Rafferty Asset Management first reported a position in CRDF in Q4 2020 and held it in 1 quarter. The position peaked at $680K in Q4 2020. 73 funds tracked by Wall St. Rank hold CRDF as of Q1 2021.

  • Rafferty Asset Management reported no remaining Cardiff Oncology position as of Q1 2021 after selling out during the quarter.
  • Rafferty Asset Management sold 37,805 Cardiff Oncology shares in Q1 2021, an estimated $680K.
  • Rafferty Asset Management first reported a position in Cardiff Oncology in Q4 2020 and held it in 1 quarter.
  • Rafferty Asset Management's Cardiff Oncology position peaked at $680K in Q4 2020.
  • 73 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2021.

Based on Rafferty Asset Management's 13F filing for Q1 2021, filed 10 May 2021.